BRAF and melanoma: Small-molecule inhibitors such as Dabrafenib and Vemurafenib, which selectively target BRAF^V600E mutations, are now standard of care for a majority of melanoma patients5,6, whereas those harboring KIT mutations benefit from Imatinib7.